In addition, it has been demonstrated that imatinib uptake in CML is dependent on OCT1 expression and the degree of OCT1 expression is considered a useful biomarker for predicting the efficacy of imatinib-based therapy in leukemia patients [326]. The gene discussed is SLC22A1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.